Wrenn Lecture: Can We Detect and Treat Alzheimer's Disease a Decade before Dementia?
Dr. Reisa Sperling is a neurologist focused on the detection and treatment of Alzheimer's disease, even before clinical symptoms are evident. Her research uses neuroimaging and cognitive tests to understand the aging brain and the earliest changes associated with Alzheimer's disease. Dr. Sperling is a professor in Neurology at Harvard Medical School, and the Director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling led the NIA-Alzheimer's Association workgroup to develop guidelines for "Preclinical Alzheimer's disease," and
currently serves on the Advisory Council of the National Institute on Aging. She
is the co-Principal Investigator, with Dr. Keith Johnson, of the Harvard Aging Brain Study in Boston. Dr. Sperling is the Project Leader for the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) study - a landmark secondary prevention trial in over 1150 clinically normal older individuals with PET amyloid imaging evidence of early Alzheimer's disease pathology. She is the co-Principal Investigator of the newly NIH funded Alzheimer's Disease Clinical
Trial Consortium (ACTC). Dr. Sperling has received the 2011 Derek Denny-Brown
Young Neurological Scholar Award, the 2015 American Academy of Neurology Potamkin Prize, and was named one of the 2017 Most Disruptive Women to Watch in Healthcare.
This Grand Rounds event is made possible by the Hans Lowenbach Memorial Fund